Domestic pharmaceutical firms keen to enter into antidiabetic market
Published: 2003-07-24 06:58:00
Updated: 2003-07-24 06:58:00
As the patent of Handok-Aventis Pharma's Amaryl (glimepiride) is already expired and its post-surveillance system will be completed in July of next year, a number of domestic firms are on the lookout for potential revenue in the domestic antidiabetic market.
Market observers say that Korea's a...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
